Search - tctmd.com

Displaying 21 - 31 of 31

Sort: Relevancy | Date

Hope for these hard-to-treat patients: more than half saw ≥ 50% decrease at 24 weeks, regardless of LDL receptor function.

News Conference News ACC 2020

Evinacumab Cuts LDL Cholesterol in Homozygous FH

Yael L. Maxwell

April 01, 2020

Alirocumab Efficacy And Safety In Adults With Homozygous Familial Hypercholesterolemia (ODYSSEY HoFH)

Presentation ACC 2020

Alirocumab Efficacy And Safety In Adults With Homozygous Familial Hypercholesterolemia (ODYSSEY HoFH)

Presenter: Dirk J. Blom

March 30, 2020

Inclisiran Data in NEJM Prompt Talk of What Comes Next

News Daily News

Inclisiran Data in NEJM Prompt Talk of What Comes Next

March 24, 2020

LEADER Analysis Reassures on Liraglutide in Diabetic Patients With Heart Failure

News Daily News

LEADER Analysis Reassures on Liraglutide in Diabetic Patients With Heart Failure

March 10, 2020

Optimal LDL levels in patients with ACS undergoing PCI

Presentation JIM 2020

Optimal LDL levels in patients with ACS undergoing PCI

Presenter: Giuseppe Musumeci

February 13, 2020

News Daily News

Long-term Evolocumab Safe, Effective for Familial Hypercholesterolemia Treatment

Yael L. Maxwell

February 12, 2020

Stent-Related Adverse Events Continue Out to 5 Years: Meta-analysis

News Daily News

Stent-Related Adverse Events Continue Out to 5 Years: Meta-analysis

Michael O'Riordan

February 10, 2020

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

News Daily News

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

Michael O'Riordan

January 14, 2020

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

News Daily News

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

Michael O'Riordan

January 03, 2020

PCSK9 Inhibitors for the Interventionalist: Which Patients Do We Choose and How Do We Use?

Presentation Cardiovascular Interventions 2019

PCSK9 Inhibitors for the Interventionalist: Which Patients Do We Choose and How Do We Use?

Presenter: Matthew J. Budoff

November 01, 2019

COVID-19 TCTMD Updates

Partner Content

COVID-19 TCTMD HUB

July 17, 2020

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.